Whitehead Institute scientists have genetically and enzymatically modified red blood cells to carry a range of valuable payloads—from drugs, to vaccines, to imaging agents—for delivery to specific sites throughout the body.
“We wanted to create high-value red cells that do more than simply carry oxygen,” says Whitehead Founding Member Harvey Lodish, who collaborated with Whitehead Member Hidde Ploegh in this pursuit. “Here we’ve laid out the technology to make mouse and human red blood cells in culture that can express what we want and potentially be used for therapeutic or diagnostic purposes.”
Lodish believes the applications are potentially vast and may include RBCs modified to bind and remove bad cholesterol from the bloodstream, carry clot-busting proteins to treat ischemic strokes or deep-vein thrombosis, or deliver anti-inflammatory antibodies to alleviate chronic inflammation.
Read more . . .
The Latest on: Engineered Red Blood Cells
[google_news title=”” keyword=”Engineered Red Blood Cells” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Engineered Red Blood Cells
- How personalized medicine is transforming your health careon May 10, 2024 at 1:42 am
micro-engineered spinal cord tissue from a patient with amyotrophic lateral sclerosis. Motor neurons (white) and a blood vessel (red), derived from the ALS patient’s stem cells, form functioning ...
- Cells collected from 1st SCD patient receiving gene therapy Lyfgeniaon May 9, 2024 at 9:53 am
Lyfgenia is a one-time gene therapy approved last year by the FDA to treat sickle cell patients, 12 and older, with a history of VOEs.
- Capricor Therapeutics to Present Exosome Platform Updates at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meetingon May 9, 2024 at 6:15 am
Preclinical findings show exosome-based therapeutic approach for the treatment of arginase-1 deficiency (ARG1-D)- -Presentation to be featured in an oral session being held on May 9, 2024- SAN DIEGO, ...
- Editas Medicine Announces First Quarter 2024 Results and Business Updateson May 8, 2024 at 12:00 am
Before joining Editas Medicine, Mr. Whitehead served as Chief Quality Officer at Rubius Therapeutics, establishing quality capabilities to support first-in-human clinical trials for genetically ...
- Bluebird, Vertex prep for first commercial use of sickle cell gene therapieson May 6, 2024 at 9:33 am
A 12-year-old boy in the Washington, D.C., area is set become the first patient treated with Lyfgenia since its U.S. approval last December.
- Bluebird preps for first commercial use of sickle cell gene therapyon May 6, 2024 at 1:01 am
Manufacturing is carried out in a central laboratory, from where the re-engineered cells are shipped back to treating ... after researchers identified changes in the protein hemoglobin that caused red ...
- Engineered universal blood made possible by bacterial enzymeson May 1, 2024 at 5:00 pm
Up to 98% of the engineered O cells that were made from ... Because there may be other important sugars on the surface of the red blood cell that are being removed that, in another context ...
- Scientists Find a Surprising Way to Transform A and B Blood Types Into Universal Bloodon April 29, 2024 at 3:16 pm
Surprisingly, the gut microbiome may hold a solution for boosting universal blood supplies by chemically converting other blood types into the universal O.
- Bacteria 'nanowires' could help develop green electronicson April 29, 2024 at 7:30 am
Engineered protein filaments originally produced by bacteria have been modified by scientists to conduct electricity. In a study published recently in the journal Small, researchers revealed that ...
- When bad cells go good: Harnessing cellular cannibalism for cancer treatmenton January 7, 2024 at 3:34 am
Indeed, cellular cannibalism is not as rare as you might expect: Millions of old red blood cells are eliminated ... macrophages' attack on cancerous cells. Clinicians hopefully won't need to worry ...
via Bing News